ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ANIK vs JNJ // FORWARD P/E MULTIPLE

Anika Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ANIK 0 — JNJ 9
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIK VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ANIK JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 56.60% 67.90% -11.30 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -10.20% 25.50% -35.70 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield 1.50% 2.97% -1.47 JNJ /fcf-yield <GO>
Operating Margin -9.80% 34.70% -44.50 JNJ /operating-margins <GO>
Net Profit Margin -9.80% 28.50% -38.30 JNJ /net-margins <GO>
Revenue Growth (YoY) -5.90% 6.00% -11.90 JNJ /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.1 62.1 -8.96 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $291.6M $662.49B -$662.20B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ANIK REV JNJ REV ANIK GROSS % JNJ GROSS % ANIK FCF JNJ FCF
FY 2025 $112.8M $94.19B 56.6% 67.9% $4.4M $19.70B
FY 2024 $119.9M $88.82B 63.4% 69.1% -$2.3M $19.84B
FY 2023 $120.8M $85.16B — — -$1.8M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIK // BETA —
JNJ // BETA 1.08